Key facts
- This page summarizes Nancy Stuart's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Oct 2025, 18:30.
Nancy Stuart - 01 Oct 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)
- Reporting relationship
- Director
- Issuer ticker
- KALV
- Reported as of
- 01 Oct 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2025, 18:30:48 UTC
- Prior SEC filing
- 04 Oct 2024
- Next SEC filing
- 11 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Benjamin L. Palleiko, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nancy Stuart filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 02 Oct 2025.
Change
- Previous filing in this sequence was filed on 04 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001594774
Primary reporting owner
Stuart Nancy
- Relationship
- Director
- Address
- C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM
- Signature
- /s/ Benjamin L. Palleiko, Attorney-in-Fact
- Signature date
- 02 Oct 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALV
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 01 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $12.05
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.